Publications
Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Dilling TJ, Dobelbower MC, Govindan R, Grannis FW, Horn L, Jahan TM, Komaki R, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Schild SE, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M, National comprehensive cancer network. Non-Small Cell Lung Cancer, Version 6.2015. Journal of the National Comprehensive Cancer Network : JNCCN. 2015. PMID: 25964637
Bol GM, Vesuna F, Xie M, Zeng J, Aziz K, Gandhi N, Levine A, Irving A, Korz D, Tantravedi S, Heerma van Voss MR, Gabrielson K, Bordt EA, Polster BM, Cope L, van der Groep P, Kondaskar A, Rudek MA, Hosmane RS, van der Wall E, van Diest PJ, Tran PT, Raman V. Targeting DDX3 with a small molecule inhibitor for lung cancer therapy. Volume 7 of Issue 5 EMBO molecular medicine. 2015. PMID: 25820276
Tempero MA. Multidisciplinary management of pancreatic cancer. Journal of the National Comprehensive Cancer Network : JNCCN. 2015. PMID: 25995435
Tempero M. Reducing costs by changing behavior-really? Journal of the National Comprehensive Cancer Network : JNCCN. 2015. PMID: 25964633
Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, Benitez CM, Bierman PJ, Blum KA, Chen R, Dabaja B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Huang J, Johnston PB, Khan N, Maloney DG, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Mulroney C, Poppe M, Rabinovitch R, Seropian S, Tsien C, Winter JN, Yahalom J, Burns JL, Sundar H, National comprehensive cancer network. Hodgkin lymphoma, version 2.2015. Journal of the National Comprehensive Cancer Network : JNCCN. 2015. PMID: 25964641
Okimoto RA, Bivona TG. AXL receptor tyrosine kinase as a therapeutic target in NSCLC. Lung Cancer (Auckland, N.Z.). 2015. PMID: 28210148
Komanduri KV. A maturing understanding of naive T cells. Blood. 2015. PMID: 25931580
Small EJ, Lance RS, Gardner TA, Karsh LI, Fong L, McCoy C, DeVries T, Sheikh NA, GuhaThakurta D, Chang N, Redfern CH, Shore ND. A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015. PMID: 25925891
Biran N, Sehgal P, Sahni G, Doucette J, Chari A. Outcome of patients with multiple myeloma and hypotension during high-dose chemotherapy. American journal of hematology. 2015. PMID: 25732327
Lin L, Bivona TG. The Hippo effector YAP regulates the response of cancer cells to MAPK pathway inhibitors. Molecular & cellular oncology. 2015. PMID: 27308535
Ko AH. Progress in the treatment of metastatic pancreatic cancer and the search for next opportunities. Volume 33 of Issue 16 Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015. PMID: 25918299
Meyerhardt JA, Tepper JE, Venook AP. Special Series: Advances in GI Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015. PMID: 25918284
Gubens MA, Burns M, Perkins SM, Pedro-Salcedo MS, Althouse SK, Loehrer PJ, Wakelee HA. A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies. Lung cancer (Amsterdam, Netherlands). 2015. PMID: 26009269
Alva A, Friedlander T, Clark M, Huebner T, Daignault S, Hussain M, Lee C, Hafez K, Hollenbeck B, Weizer A, Premasekharan G, Tran T, Fu C, Ionescu-Zanetti C, Schwartz M, Fan A, Paris P. Circulating Tumor Cells as Potential Biomarkers in Bladder Cancer. The Journal of urology. 2015. PMID: 25912492
Chang YH, Korkola J, Amin DN, Moasser MM, Carmena JM, Gray JW, Tomlin CJ. Disentangling multidimensional spatio-temporal data into their common and aberrant responses. PloS one. 2015. PMID: 25901353
Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A, KEYNOTE-006 investigators. Pembrolizumab versus Ipilimumab in Advanced Melanoma. The New England journal of medicine. 2015. PMID: 25891173
Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L, KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. The New England journal of medicine. 2015. PMID: 25891174
Rivera LB, Meyronet D, Hervieu V, Frederick MJ, Bergsland E, Bergers G. Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy. Cell reports. 2015. PMID: 25892230
Elkabets M, Pazarentzos E, Juric D, Sheng Q, Pelossof RA, Brook S, Benzaken AO, Rodon J, Morse N, Yan JJ, Liu M, Das R, Chen Y, Tam A, Wang H, Liang J, Gurski JM, Kerr DA, Rosell R, Teixidó C, Huang A, Ghossein RA, Rosen N, Bivona TG, Scaltriti M, Baselga J. AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas. Cancer cell. 2015. PMID: 25873175
Levy JA. Dispelling myths and focusing on notable concepts in HIV pathogenesis. Trends in molecular medicine. 2015. PMID: 25883070